New antituberculosis drugs: from clinical trial to programmatic use
Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-06-01
|
| Series: | Infectious Disease Reports |
| Subjects: | |
| Online Access: | http://www.pagepress.org/journals/index.php/idr/article/view/6569 |